Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment Eisai Aug 04, 2023 12:04 HKT/SGT Read More
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023（AAIC2023）において発表 Eisai Jul 20, 2023 13:00 JST Read More
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 Eisai Jul 20, 2023 10:23 HKT/SGT Read More
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research Eisai Jul 12, 2023 09:05 HKT/SGT Read More
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease Eisai Jul 07, 2023 12:21 HKT/SGT Read More
エーザイとバイオジェン・インク、「LEQEMBI(R)」（レカネマブ）がアルツハイマー病治療薬として米国FDAよりフル承認を取得 Eisai Jul 07, 2023 09:00 JST Read More
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced Eisai Jun 30, 2023 10:08 HKT/SGT Read More
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development BioMed X Institute Jun 29, 2023 17:00 HKT/SGT Read More
エーザイ、Gates Ventures、Health Data Research UK、LifeArc、およびエジンバラ大学は認知症の課題解決に寄与するデジタル・ソリューション開発をめざす共同研究「NEURii」を開始 Eisai Jun 29, 2023 12:00 JST Read More
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City Eisai Jun 22, 2023 16:08 HKT/SGT Read More
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease Eisai Jun 12, 2023 09:13 HKT/SGT Read More
エーザイ、米国FDA諮問委員会は全会一致でアルツハイマー病治療薬「LEQEMBI(R)」（レカネマブ）の臨床上のベネフィットを支持 Eisai Jun 12, 2023 09:00 JST Read More
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea Eisai Jun 08, 2023 12:32 HKT/SGT Read More
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、韓国において早期アルツハイマー病に係る適応で新薬承認を申請 Eisai Jun 08, 2023 09:00 JST Read More
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting Eisai Jun 02, 2023 11:20 HKT/SGT Read More
アバンセ・クリニカルがASCO & BIO 2023に参加 初期段階のオンコロジー試験はより精緻化、より多くの患者を必要とする Avance Clinical May 30, 2023 20:00 JST Read More
